Program
suzetrigine
Also written as “Suzetrigine”, “VX-548” and “SUZ”.
Its studies are mostly in Pain · Acute Pain · Neuralgia · Radiculopathy, led by 2 companies.
Drug pageSuzetrigine: every studyAll 57 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 263 open or running | phase 4since Mar 19, 2025 | Jul 15, 2021 | Jan 25, 2027phase 3 · NCT06696443 |
| Latigo Biotherapeuticsits history only | 10 open or running | early phase 1since May 6, 2025 | May 6, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Vertex Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Jul 15, 2021.
- Dec 14, 2022Phase 3 study in PainNCT05661734 · 258 enrolled · United States
- Jan 19, 2023Phase 1 study in PainNCT05704556 · 38 enrolled · United States
- Jan 19, 2023Named suzetrigineINNProposed as its International Nonproprietary Name in WHO's List 128 · before, VX-548
- Apr 5, 20232 phase 1 studies in PainNCT05818852, NCT05851157
- Dec 10, 2023Phase 2 study in Painful Lumbosacral RadiculopathyNCT06176196 · 218 enrolled · United States
- Mar 21, 2024Phase 1 study in PainNCT06336096 · 48 enrolled · United States
- May 14, 2024Phase 1 study in PainNCT06420765 · 92 enrolled · United Kingdom
- Sep 30, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainNCT06628908 · 1,100 planned · United States
- Nov 15, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainNCT06696443 · 455 enrolled · United States
- Feb 5, 20252 phase 1 studies in PainNCT06820307, NCT06834009
- Mar 19, 20252 phase 4 studies in Acute PainNCT06887972, NCT06887959
- Nov 13, 2025Phase 3 study in Diabetic Peripheral Neuropathic PainNCT07231419 · 734 planned · United States
- Jan 23, 2026Phase 1 study in PainNCT07378865 · 13 enrolled · United States
- Apr 13, 2026Phase 4 study in PainNCT07538570 · 66 enrolled · United States
- Apr 29, 2026Phase 1 study in PainNCT07570069 · 18 enrolled · United States
Ahead
- Jan 25, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainNCT06696443
- Apr 6, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainNCT07231419
- May 31, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainNCT06628908
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 Vertex Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07570069Pain · United States | 1 | Completed | Jul 16, 2026 | 18 |
| NCT07538570Pain · United States | 4 | Completed | Oct 12, 2026 | 66 |
| NCT07378865Pain · United States | 1 | Completed | Aug 17, 2026 | 13 |
| NCT07231419Diabetic Peripheral Neuropathic Pain · United States | 3 | Recruiting | Apr 6, 2027 | 734 |
| NCT06887972Acute Pain · United States | 4 | Completed | Oct 24, 2025 | 100 |
| NCT06887959Acute Pain · United States | 4 | Completed | Oct 27, 2025 | 47 |
| NCT06834009Pain · United States | 1 | Completed | Apr 24, 2025 | 10 |
| NCT06820307Pain · United States | 1 | Completed | Apr 29, 2025 | 50 |
| NCT06696443Diabetic Peripheral Neuropathic Pain · United States | 3 | Active, not recruiting | Jan 25, 2027 | 455 |
| NCT06628908Diabetic Peripheral Neuropathic Pain · United States | 3 | Recruiting | May 31, 2027 | 1,100 |
| NCT06420765Pain · United Kingdom | 1 | Completed | Mar 22, 2025 | 92 |
| NCT06336096Pain · United States | 1 | Completed | Jun 19, 2024 | 48 |
| NCT06176196Painful Lumbosacral Radiculopathy · United States | 2 | Completed | Oct 2, 2024 | 218 |
| NCT05851157Pain · United States | 1 | Completed | Oct 30, 2023 | 73 |
| NCT05818852Pain · United States | 1 | Completed | Jun 12, 2023 | 72 |
| NCT05704556Pain · United States | 1 | Completed | Mar 30, 2024 | 38 |
| NCT05661734Pain · United States | 3 | Completed | Dec 12, 2023 | 258 |
| NCT05660538Diabetic Peripheral Neuropathy · United States | 2 | Completed | Oct 12, 2023 | 194 |
| NCT05635110Pain · Australia | 1 | Completed | Jun 8, 2023 | 31 |
| NCT05560464Pain · United States | 1 | Completed | Jul 24, 2023 | 36 |
| NCT05558410Acute Pain · United States | 3 | Completed | Aug 25, 2023 | 1,118 |
| NCT05553366Acute Pain · United States | 3 | Completed | Dec 15, 2023 | 1,075 |
| NCT05541471Pain · United States | 1 | Completed | Apr 16, 2023 | 37 |
| NCT05455502Pain · United States | 1 | Completed | Sep 17, 2022 | 24 |
| NCT05034952Acute Pain · United States | 2 | Completed | Dec 5, 2021 | 303 |
| NCT04977336Acute Pain · United States | 2 | Completed | Feb 17, 2022 | 274 |
How it is read
Names in the registry
- “Suzetrigine”, 13 entries
- “VX-548”, 11 entries
- “SUZ”, 2 entries
- “suzetrigine 100mg”, 1 entry
- “Suzetrigine (SUZ)”, 1 entry
Codes read as this program: VX548.
Conditions, from the studies’ own filings
- Pain, 16 studies
- Acute Pain, 6 studies
- Neuralgia, 3 studies
- Radiculopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.